Novo Nordisk stock rises; Hims & Hers pulls copycat weight-loss pill

Novo Nordisk shares rose 8% on Monday after Hims & Hers said it would pull its counterfeit weight-loss pill from the market.

Wegovy’s manufacturer, Novo Nordisk, and the US Food and Drug Administration had threatened to take legal action against Hims & Hers, which announced over the weekend that it would not sell the pill.

“Since launching the compounded semaglutide pill on our platform, we have had constructive discussions with industry stakeholders,” Hims & Hers said. sent on social media on Saturday.

“As a result, we have decided to discontinue providing access to this treatment. We remain committed to the millions of Americans who rely on us for access to safe, affordable and personalized care.”

This is breaking news. Please refresh for updates.